Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Withdrawn 1Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Leukemia, Myeloid, Acute 19Breast Neoplasms 17Advanced Solid Tumors 16Advanced Solid Tumor 12Carcinoma, Non-Small-Cell Lung 10Myelodysplastic Syndromes 9Uterine Cervical Neoplasms 6Solid Tumor 6Recurrence 6Prostatic Neoplasms 6Lymphoma, Large B-Cell, Diffuse 6Triple Negative Breast Neoplasms 5Stomach Neoplasms 5Ovarian Neoplasms 5Carcinoma, Hepatocellular 5Small Cell Lung Carcinoma 4Myeloproliferative Disorders 4Multiple Myeloma 4Advanced Solid Tumour 4Advanced Malignant Solid Tumor 4Solid Tumors 3Precursor Cell Lymphoblastic Leukemia-Lymphoma 3Neoplasms 3Lymphoma, Non-Hodgkin 3Lymphoma 3Leukemia, Myelomonocytic, Chronic 3Biliary Tract Neoplasms 3Advanced Lung Cancer 3Squamous Cell Carcinoma of Head and Neck 2Sarcoma 2

Interventions

Cyclophosphamide 11venetoclax 10Dexamethasone 8Cytarabine 7Vincristine 5Azacitidine 4mogamulizumab 3fludarabine phosphate 3fludarabine 3daratumumab 3Specimen Handling 3Prednisone 3Methotrexate 3Doxorubicin 3Dasatinib 3Biopsy 3ruxolitinib 2prednylidene 2pegaspargase 2nelarabine 2deltacortene 2calaspargase pegol 2Rituximab 2Mercaptopurine 2Etoposide 2Decitabine 2Daunorubicin 2Calcium Dobesilate 2Bortezomib 2Asparaginase 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Precursor T-Cell Lymphoblastic Leukemia-Lymphoma × Injections × Clear all
NCT06376721 2024-04-19

Linperlisib Combined With Camrelizumab and Pegaspargase in Advanced or Relapsed/Refractory NK/T-cell Lymphoma

Beijing Tongren Hospital

Phase 1/2 Recruiting
43 enrolled
LymphoidOther hematologic neoplasm

Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡